The release of the first long-term survival data for head and neck squamous cancer has brought new hope to patients.

Immunotherapy, as a supernova in the field of tumor therapy in recent years, has been approved for adaptation has covered more than ten kinds of solid tumors and blood tumors.
at the recent European EsMO, immunotherapy was even more remarkant, publishing the results of long-term follow-up to a number of heavy-weight studies.
this undoubtedly shows the possibility of immunotherapy for long-term survival, bringing new expectations to academia and patients.
addition to the positive results of long-term follow-up to lung cancer and melanoma, head and neck squamous cancer also released four-year survival data, continuing to break through to five-year survival.
believe that in the near future, there will be a large number of cancers through immunotherapy to improve the five-year survival rate, to get rid of the poor prognosis of the "terminal" hat, including head and neck squamous cancer.
is head and neck squamous cancer? Head and neck squamous cancer is a tumor with high immunodeficiency, and more than 70% of patients have been diagnosed in the middle and late stage, the tumor appears local lymph node metastasis or distant metastasis, the use of surgery or radiotherapy is not ideal efficacy, 5-year survival rate of less than 40%.
More regrettable, after receiving standard treatment for patients with local late-stage head and neck squamous cancer, the local recurrence rate was about 50% to 60%, the distant metastasis recurrence rate was about 4% to 26%, and the therapeutic effect was not satisfactory.
head and neck squamous cancer pathology type is squamous cell carcinoma (squamous cancer), the general sensitivity to conventional drug treatment such as chemotherapy, may be one of the reasons for the treatment effect is not ideal, the need for more targeted new drugs to open a breakthrough.
immunotherapy has proved superior to the efficacy of standard chemotherapy programs in lung, esophageal and head and neck squamous cancers, and has been approved for a variety of squamous cancer adaptation certificates, demonstrating a clear preference for squamous cancer, bringing a new dawn to the treatment of squamous cancer.
year's ESMO, the KEYNOTE-048 study updated a new breakthrough in the four-year survival rate of long-term follow-up, bringing a new dawn of long-term survival for patients with head and neck squamous cancer.
Long Survival Leap keyNOTE-048 study of head and neck squamous cancer is a Phase III clinical trial that confirms that paboliju monotherapy and combined chemotherapy can significantly extend survival compared to conventional treatment options for first-line treatment of patients with relapsed or metastatic head and neck squamous cancer.
With excellent data results, Pabli Juju won two FDA-approved first-line accreditation certificates for head and neck squamous cancer in June 2019, and has been recommended by the NCCN (National Integrated Cancer Network) guidelines and the CSCO (China Society of Clinical Oncology) guidelines, whether it's single-drug or combined chemotherapy.
"The KEYNOTE-048 study is a cross-era study of head and neck squamous cancer, which has established the classic position of Paboli Pearl single-line treatment for recurrence metastatic head and neck squamous cancer," said Professor Guo Wei, Deputy Director of the Department of Oncology and Director of phase I Clinical Trials Center at Tongji University's Oriental Hospital.
patients with PD-L1-positive (CPS≥20) were significantly better than traditional chemotherapy combination-targeted treatments with Pabliju monoantigen, and the first line could be free of chemotherapy.
" there is no doubt that paboliju monoantigen use can bring accurate efficacy and lower adverse reactions to treatment options for patients with head and neck squamous cancer.
in PD-L1-positive populations, Pabliju monoantigen compared to conventional treatment, the total survival period was extended by 4.1 months (14.9 months vs 10.8 months), a 39% reduction in disease Risk of death; mitigation duration more than 5 times (23.4 months vs 4.2 months), four-year survival rate nearly three times (21.6% vs 8.0%), resulting in sustained long-term survival benefits.
Paboliju monoantimmune relative to conventional treatment options, the safety is better, the rate of adverse reactions of level 3 and above is only a quarter (17.0% vs 69.3%), patients feel better use.
even more impressive, about half of the patients in the KEYNOTE-048 study received follow-up treatment, and patients with Pabliju monotherapy had a longer second progression-free life (11.7 months vs. 9.4 months).
means that patients with head and neck squamous cancer choose to use Paboliju monotherapy early, but also for follow-up treatment to increase, continue to gain survival benefits, help long-term survival.
, The application for the listing of the first-line treatment of head and neck squamous cancer has also been submitted to the State Drug Administration and has been included in the priority review list.
look forward to the approval of the next new adaptation certificate of Paboli Pearl single resistance, for China's head and neck squamous cancer patients to light up new hope for treatment, for the long road to long-term anti-cancer guidance.
.